Pimobendan Manufacturer CAS 74150-27-9 with Purity 99%

Min.Order / FOB Price:Get Latest Price

1 Kilogram	FOB Price:USD 4.8000 -5.0000

1 Kilogram

FOB Price:USD 4.8000 -5.0000

Min.Order :1 Kilogram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,Other

Keywords

Pimobendan 74150-27-9 Pimobendan powder

Quick Details

Appearance:White powder
Application:Blood lipid regulation, anti - atherosclerosis drugs
PackAge:25KG/DRUM
ProductionCapacity:1000|Kilogram|Year
Storage:Store at +4°C
Transportation:General cargo transport

Superiority:

We are concentrating on APIs and pharmaceutical intermediates.

It is made obtainable from us at the most reasonable rate.

Our Service:

1. Rich experience: Our company is a professional production leading factory in China in pharmaceutical area of manyyears.

2. Top quality: High quality guaranteed, once any problem is found, the package would be reshipped for you .

3. Security Shipping: Shipping by express (FedEx,UPS,DHL,EMS), by air, by sea. The most professional forwarder would be recommanded for you.

4. Fast delivery: We have stock, so we can delivery quickly once payment is received.

5. Quality service: We will give you warm after-sale service,if any question we will reply you within 24 hours.

6. Competitive prices: A discount would be given when you make a large order.

Details:

Company Profile:

Company name: Hanways ChemPharm Co., Ltd.

Year Establishment: 2009

Location: 18-1-802, Green Garden, Jianghan District, Wuhan 430023, China

Main product:
- API: Antiobesity; Oncology; Antiviral; Cardiovascular; Antibiotics; Antidiabetics and others
- Peptides
- Hormones
- Intermediates

Product Name: Pimobendan

CAS: 74150-27-9

MF: C19H18N4O2

MW: 334.37

EINECS: 640-420-7

Appearance: White powder

Pimobendan, a novel cardiotonic vasodilator, was introduced in Japan for the treatment of acute and mild to moderate chronic heart failure. It is a phosphodiesterase Ⅲ inhibitor and is able to enhance sensitization of myocardial contractile regulatory protein to calcium ions. The combination of these effects contribute to its inotropic activity. In patients with severe congestive heart failure, orally administered pimobendan improves cardiac index, stroke volume index, pulmonary wedge pressure, and systemic and pulmonary vascular resistance. Pimobendan is reported to be well tolerated and largely devoid of the proarrhythmic effects of classical phosphodiesterase Ill inhibitors. Studies also suggested that combination of the inotropic agent pimobendan with an ACE inhibitor such as enalapril may be superior to monotherapy for heart failure patients.

Our Factory:

View All

Visit Store